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Many strains of Group A streptococci elaborate into the medium in which 
they are grown an enzyme that catalyzes specifically the cleavage of diphos- 
phopyridine nucleotide (DPN)  t (1, 2). The studies now to be described demon- 
strate that this enzyme when injected into rabbits or guinea pigs stimulates the 
production of antibodies that neutralize the ability of the enzyme to destroy 
DPN.  Moreover,  similar  neutralizing  antibodies  have  been  detected  in  the 
blood serum of a  high percentage of randomly selected hospital patients,  and 
the titer of these antibodies was found to rise sharply following known strepto- 
coccal infections. 
Materials and Methods 
Antibodies directed against streptococcal DPNase, hereafter referred  to as 
ASDA, were assayed by measuring the ability of serial dilutions of serum to 
inhibit the DPN-destroying activity of a known concentration of the enzyme. 
Optimal conditions for the assay procedure were determined, and the test was 
applied  to blood serum obtained from experimental animals before and after 
specific  immunization, and to serum from a  large number of human beings. 
Streptococcal DPNase.--Streptococcal preparations containing DPNase were generously 
supplied by Dr. Alan W. Bernheimer of the Department of Microbiology,  New York Univer- 
sity College of Medicine. These were for the most part fractionated culture supernates pre- 
pared from 15 liter cultures of the C203S strain of Group A streptococcus according to the 
method previously described (3). The streptococcal preparations were dialyzed overnight 
against tap water prior to use. The dialyzed solutions maintained their DPNase activity for 
as long as 1 month when stored at 4°C. Dilutions of the dialyzed material were made in a 
* These studies were supported in part by research grants from the National Heart Insti- 
tute of the United States Public Health Service and the New York Heart Association. 
The authors wish to acknowledge the helpful assistance of Miss Helen Sammet throughout 
these studies. 
1  DPN was obtained from Sigma Chemical Co., St. Louis; its purity ranged from 90 to 
95 per cent. 
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potassium phosphate buffer at pH 7.3 containing 0.1 per cent bovine serum albumin (Armour). 
Crude culture filtrates and fractions separated  by continuous flow paper electrophoresis were 
used on several occasions and found to be satisfactory. 
Assay o/DPNase Acli~ity.--DPNase  activity was measured by the method of Kaplan, 
Colowick, and Nason  (4), slightly modified as described in a  previous publication (1). The 
unit of DPNase activity was defined as the amount of enzyme that destroys 0.01 #~ DPN in 
7~  minutes at  37°C. 
Measurement of Antibodies to Streptococcal DPNase  (ASDA).--A  dialyzed  streptococcal 
preparation was assayed for DPNase activity and diluted with buffer solution to a concentra- 
tion of about 350 DPNase units per ml. Serial twofold dilutions of the serum to be tested were 
made in buffer solution, and 0.5 ml. of each serum dilution was placed in a test tube together 
with 0.5  ml. of the appropriately diluted enzyme solution. Serum dilutions of  1-4 through 
1-64 were adequate to span the range of antibody titers usually encountered. In those cases, 
however, in which the titers were very low, undiluted serum or a  1-2 dilution was employed, 
and higher dilutions than 1-64 were necessary in those instances in which the titer of anti- 
body was elevated. Two control tubes each containing 0.5 ml. of DPNase solution and 0.5 ml. 
of buffer were included in each run. The mixtures of serum or buffer solution and DPNase 
were incubated for 30 minutes in a  water bath at 37°C.  The amount of residual DPNase 
activity was then determined by taking 0.2 ml. of each mixture and adding it to a  tube con- 
taining 0.4 mg. DPN  (0.3  ml. of a  DPN solution containing 1.33 rag. per mi.). In practice 
it was found expedient to pipette the DPN into tubes kept in an ice water bath while  the 
serum and DPNase mixtures were incubating, and then rapidly to transfer 0.2 ml. of each 
mixture into the tube containing the DPN solution. These tubes were incubated for 7~ min- 
utes in a  water bath at 37°C.  The reaction was stopped by plunging the tubes into an ice 
water bath, and 3.0 ml. of 1 x~ sodium cyanide was added immediately to each tube. Optical 
density was measured in a  Beckman DU spectrophotometer at 340 m/~ using 1.0 cm. corex 
cuvettes. Suitable blanks and DPN standards were included in all determinations. 
Sera were stored in the liquid state for several weeks and in the frozen state for several 
months without loss of ASDA activity. Heating the serum at 63°C. for 5 minutes to inacti- 
vate complement had no appreciable effect on the ASDA activity. 
Numerous control studies revealed that serum from rabbits, guinea pigs, or  human beings 
had no appreciable DPNase activity under the conditions employed. In other control studies, 
the mixtures of serum and DPNase solution were incubated at different temperatures from 
4°-56°C. and for periods of time ranging from 5 minutes to 24 hours. At temperatures above 
37°C.  the enzyme, known to be quite heat-labile, was  inactivated even in the  absence of 
serum. At temperatures below 37°C.,  the reaction between serum and enzyme often failed 
to go to completion. Incubation for 30 minutes at 37°C. was found to be optimal, and there 
was  no  significant change in  the  reaction between  serum  and  enzyme on  prolonging  the 
incubation period beyond this point. 
The anti-DPNase titer was calculated from the reduction in DPNase activity of the enzyme 
solution following incubation with an appropriate dilution of the serum. Since the estimation 
of DPNase by the cyanide method of Kaplan, Colowick, and Nason (4) is not linear beyond 
the point at which 60 per cent of the DPN substrate is split, ASDA activity was calculated 
only from those mixtures of diluted serum and enzyme which, after incubation with DPN, 
had optical density readings in the range of 0.400 to 0.600. The unit of ASDA activity was 
arbitrarily defined as that amount of antibody per ml. of serum that neutralized 100 units of 
streptococcal DPNase. This unit was adopted both for the sake of convenience and to make 
it more readily comparable with the widely employed units for measuring antibodies to strep- 
tolysin O  (5). With undiluted serum, the test was capable of detecting as little as one unit of 
ASDA activity. When serial dilutions of  serum were  employed,  the  results were generally 
reproducible within a range of plus or minus 30 per cent. A.  KELLNER~  E.  B.  FREEMAN~  AND  A.  S.  CARLSON  301 
EXPERIMENTAL 
Immunization of Rabbits and Guinea Pigs to Streptococcal DPNase.--To learn 
whether  antibodies to  streptococcal  DPNase  could be  produced  in animals, 
an  experiment  was  done  in  which  a  streptococcal  preparation  containing 
DPNase was injected into rabbits and guinea pigs, and serum obtained from 
these animals was tested for its ability to inhibit the enzyme. 
Six normal hybrid rabbits weighing 2.5 to 3 kilos were each given an initial series of 5 intra- 
venous injections. The injections were given every other day, and each injection  consisted 
of 0.5 ml. of a streptococcal preparation  containing 15,000 DPNase units. The animals were 
bled just prior to the first injection, and again 3 weeks and I0 weeks later. At the 10th week, 
TABLE I 
Immunization of Rabbits to Streptococcal DPNase 
0  3 wks.  10 wks.  11 wks.  14 wks. 
Rabbit No. 
ASDA unils/ral. 
<1 
<1 
<1 
<1 
<I 
<1 
12 
3 
<1 
<1 
4 
<1 
23 
2 
<i 
5 
9 
<I 
1350 
360 
25 
33 
250 
10 
235 
170 
21 
23 
265 
10 
Each rabbit was given initially an intravenous injection every other day for a total of 5 
injections of 0.5 ml. of a streptococcal preparation  containing 15,000 DPNase units, and a 
booster injection in the same dosage at the 10th week. 
0, just prior to the first injection. 
ASDA, antistreptococcal DPNase. 
each rabbit was given a single booster injection intravenously of 0.5 ml. of the same prepa- 
ration containing 15,000 DPNase units, and the animals were bled again at the llth and 14th 
week after the onset of the experiment. In another experiment, 6 normal male guinea pigs 
weighing 400 to 800 grams were each bled from the heart, and then given two intraperitoneal 
injections 2 weeks apart of 0.5 ml. of a partially purified streptococcal preparation  contain- 
Lug 90,000 DPNase units per ml. Four weeks after the second injection they were again bled 
from the heart and the sera obtained before and after immunization were assayed for the 
presence of antibodies to DPNase. 
From the data contained in Table I  it is clear that following the injection of 
streptococcal  DPNase  the  rabbits  developed  antibodies  that  inhibited  the 
activity of the enzyme. Three animals responded promptly and had measurable 
ASDA activity in their sera 3 weeks after the initial injections; one animal had 
antibodies when tested  on  the  10th  week;  in the  two  remaining animals no 
antibodies were detectable either on the 3rd or 10th week after the injections. 
All six  animals, however,  had  measurable levels of  ASDA activity after  the 302  ANTIBODIES  TO  STREPTOCOCCAL  DPI~ASE 
booster injection. Similarly, five of the six guinea pigs had measurable ASDA 
activity in their serum following intraperitoneal injection of DPNase. It is of 
interest that none of the animals in these experiments had detectable ASDA 
activity in their serum prior to the injection of DPNase. In subsequent studies, 
sera from numerous normal rabbits, guinea pigs, and rats were tested for ASDA 
activity;  these  were  uniformly  negative.  On  the  other  hand,  measurable 
amounts of ASDA were found in the serum of four rabbits injected with live or 
dead streptococci of a strain known to produce DPNase.  2 It is also noteworthy 
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that in several experiments rabbit serum capable of neutralizing large amounts 
of streptococcal DPNase failed to inhibit the DPNase of Neurospora  crassa. 
Antibodies to Streptococcal DPNase in the Serum of Randomly Selected Eospital 
Patients.--The  finding  that  streptococcal  DPNase  was  antigenic  and  that 
antibodies capable of neutralizing the enzyme could be detected in the serum 
of animals following immunization suggested that similar antibodies might also 
be present in the serum of human beings, particularly since many strains of 
Group A streptococci isolated from human beings have been shown to produce 
DPNa.se when grown in vitro (2). 
For these sera the authors are indebted to Dr. Armine  T. Wilson of the Alfred I. du Pont 
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Sera from 240 hospital patients were assayed for ASDA activity. The sera were selected 
at random from blood specimens sent to the Serology Laboratory of the New York Hospital, 
and virtually all were from adult male and female patients suffering from a wide variety of 
disease  states. Without exception,  all the sera examined  had measurable ASDA activity. 
The titers covered a wide range, as illustrated in Fig. 1. In general,  80 per cent of the sera 
had ASDA titers of S0 units or less, l0 per cent were in the range between 50 and 100 units, 
and 10 per cent had 100 units or more. It is of interest, too, that two sera that were exceed- 
ingly active in neutralizing streptococcal DPNase failed to inhibit Neurospora DPNase. 
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FIo. 2.  Anti-DPNase titem of infants, young children, and randomly selected adult hospi- 
tal patients. The horizontal interrupted lines represent the median titer in each group. 
The presence of ASDA activity in all of the sera from adult human  beings 
that were examined was not unexpected in view of the widespread prevalence 
of infections with Group A  streptococci. The possibility was considered, how- 
ever, that the ASDA activity might also be due, at least in part, to non-specific 
inhibitors of the enzyme rather than to antibodies resulting from exposure to 
DPNase-producing streptococci. It appeared of interest, therefore, to examine 
sera from infants and young children who because of their age were less likely 
to have had repeated streptococcal infections. 
Serum was obtained from 45  specimens of blood from the umbilical cord of 
newborn infants and from infants under 6 months of age, and from 14 children 
6 months to 5 years of age. Six months was arbitrarily selected as the dividing 
line because maternal  antibodies may survive in the offspring up to this age. 304  ANTIBODIES TO STREPTOCOCCAL DPI~ASE 
Sera from 62 randomly selected adult hospital patients were included for pur- 
poses of comparison. The ASDA titers of these sera are illustrated in Fig.  2. 
The sera from umbilical cord blood and from infants under 6 months of age had 
a fairly wide range of ASDA activity, similar to that of the adult population. 
The ASDA levels in this age group presumably reflected those of the maternal 
serum. The sera from children between 6 months and 5 years,  with only a few 
exceptions, had exceedingly low ASDA titers. In fact, 4 of these sera had no 
measurable ASDA activity at all. It is worthy of note that of all the sera ex- 
amined from human beings these were the only ones in which ASDA activity 
could not be detected on repeated test. It is perhaps significant, too, that the 
serum with the highest level in the age group under 6 months (138 units) and 
the one with the highest level in the age group 6 months to 5 years (298 units) 
TABLE  II 
Serum ASDA Levds of Normal Healthy Adults 
J  I 
,wk.  t  2wks.  3wks.  t  4wk~.  Swk~.  6wk~. 
Subject 
I  I 
ASDA unltS/ml. 
E.B.F ............ 
H.S  .............. 
E.P  .............. 
S.H.S  ............ 
A.K  .............. 
S. J. H ............ 
R.L.H ........... 
14 
9 
23 
23 
27 
3 
12 
10 
28 
15 
22 
21 
2 
13  14 
9  11 
28  20 
14  15 
24  22 
26  26 
3  3 
13 
22 
15 
23 
21 
2 
18 
13 
24 
13 
28 
24 
2 
ASDA, antistreptococcal DPNase. 
were both from children with fibrocystic disease of the pancreas who had had 
repeated severe respiratory tract infections.  The findings in  this  study were 
consistent with the hypothesis that the anti-DPNase activity demonstrable in 
serum from human beings was due to the presence of antibodies resulting from 
exposure to streptococcal infections. 
A  study was  then done of ASDA activity in the serum of normal human 
beings to learn whether it fluctuated significantly during a  period of several 
weeks in  the absence of overt upper respiratory tract infections. 
Seven normal adult human beings, 3 males and 4 females, were bled at weekly intervals 
for 6 weeks and the sera assayed for ASDA activity. All the subjects had been free of upper 
respiratory tract infections for at least 1 month prior to the drawing of the first specimen of 
blood, and they had no clinically  evident respiratory tract infections during the ensuing 6 
week period. The ASDA levels of these individuals, listed in Table 1I, ranged from 2 to 28 
units per mi. In any one individual, however, the ASDA levels varied only within relatively 
narrow limits during the period of observation. A.  KELLNER~  E.  B.  FREEMAN~  AND  A.  S.  CARLSON  305 
TABLE  III 
ASDA  Levels oJ Serum  From  Patients  with  Known  Streptococcal Infections 
Case No. 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
Streptococcus type 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
12 
14 
14 
14 
14 
14 
14 
19 
19 
19 
19 
19 
28 
30 
30 
30 
30 
30 
Acute illness  Convalescence 
ASDA units/ml. 
52 
22 
88 
100 
34 
110 
120 
105 
21 
105 
153 
59 
190 
168 
63 
370 
135 
57 
15 
530 
55 
43 
90 
117 
23 
54 
90 
170 
250 
70 
88 
880 
115 
540 
265 
245 
470 
25 
270 
120 
130 
170 
150 
580 
196 
440 
440 
370 
3000 
155 
140 
140 
930 
1300 
245 
120 
226 
34 
310 
230 
220 
350 
210 
880 
1710 
400 
ASDA, antistreptococcal DPNase. 
Acute illness, serum obtained at the onset of clinical symptoms or 1 or 2 days thereafter. 
Convalescence, serum obtained about 3 weeks after the initial specimen. 306  ANTIBODIES  TO  STREPTOCOCCAL  DPN'ASE 
TABLE  IV 
Comparison of ASDA and ASO Titers of Patients writ Known Streptococcal Infections 
Case No.  Titer  1 day  21 days  35 days  60 days 
1 
~0 
11 
12 
13 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
ASDA 
ASO 
298 
100 
120 
250 
140 
1250 
610 
250 
260 
833 
170 
2500 
525 
250 
136 
580 
250 
80 
166 
290 
100 
63 
125 
650  580 
500 
--  500 
--  625+ 
220 
625 
110 
625 
1130 
380 
250 
7 
100 
II 
125 
59 
125 
189 
500 
2450 
333 
330 
625+ 
430 
625+ 
625+ 
2900 
500 
260 
833 
3600 
625+ 
360 
130 
240 
550 
300 
650 
510 
170 
289O 
39O 
94 
190 
1600 
217 
ASDA, antistreptococcal DPNase, units per ml. 
ASO, antistreptolysin O, hemolytic units per mL 
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ASDA Levels Following Infection  witk Group A  Streptococci.--To  learn the 
effect  of  exposure  to  Group  A  streptococci on  the  anti-DPNase  activity of 
human serum, a  study was made of the ASDA levels of blood taken during the 
acute illness and again during convalescence from patients with known strepto- 
coccal infections. 
Sera from 33 patients with Group A streptococcal infections of known type were obtained 
during the acute phase of the illness, and again approximately 3 weeks later. These sera were 
generously supplied by Dr. Charles H. Rammelkamp, Jr. The ASDA levels of these sera are 
listed in Table HI. It is evident that in most cases there was a sharp rise in serum ASDA level 
following the streptococcal infection  and that in the majority the increase in titer was two- 
fold or more. It was unfortunately not possible to test the organisms isolated from these pa- 
tients for ability to produce DPNase in vitro. A good many of the ASDA levels were high even 
during the acute phase of the illness; these probably represent an anamnestic response, since 
it is likely that the patients were harboring the streptococci for several days prior to the onset 
of clinical symptoms and the drawing of the initial blood specimen. 
The findings of the foregoing study made it plain that serum ASDA levels 
increased sharply in most, though not in all, instances following a streptococcal 
infection. This is in keeping with the observation of Bernheimer, Lazarides, and 
Wilson that 58 per cent of strains of streptococci examined by them produced 
DPNase  in vitro (2).  The  most  thoroughly investigated of the  streptococcal 
antibodies thus far is antistreptolysin O  (ASO), and clinical studies have shown 
that some 80 per cent of patients develop significant increases in titer of ASO 
following streptococcal infections (6). It was of interest, therefore, to compare 
the changes in titer of ASDA with those of ASO in patients exposed to Group A 
streptococci. 
Comparisons of ASDA and ASO Levels in Patients with Group A Streptococcal 
lnfections.-- 
Serum was obtained from  13 patients with acute streptococcal infections at the onset of 
the illness and 21, 35, and 60 days thereafter. These sera were kindly provided by Dr. Gene 
H. Stollerman. Group A streptococci were cultured from the throat in each ease, though more 
specific typing of the organisms was not possible.  The ASO titers were  performed  in Dr. 
Stollerman's laboratory by a  modification  of the method of Rantz and Randall (5).  The 
ASDA and corresponding ASO levels of these sera are contained in Table IV. In all 13 cases 
there was a substantial rise in ASO titer, and in 8 of these there was a concomitant increase 
in ASDA activity. In the remaining 5 cases (numbers  3, 4, 6, 9, and 13) the ASDA levels 
remained essentially unchanged  despite the increase in ASO. In another series of cases, not 
listed in Table IV, ASDA and ASO levels were found, in general,  to increase in parallel fol- 
lowing streptococcal infections.  In a few instances,  however, both antibody levels remained 
essentially unchanged,  and in several cases the ASDA titer rose and the ASO titer did not. 
DISCUSSION 
Antisera produced  in rabbits and  guinea pigs by the injection of partially 
purified streptococcal preparations containing DPNase inhibit selectively the 308  ANTIBODIES  TO  STREPTOCOCCAL  DPNASE 
biological activity of the enzyme, as the studies  here described  have demon- 
strated. Similar inhibitory activity directed against streptococcal DPNase was 
found to be present in the serum of a very large percentage of human beings and 
to  increase  strikingly following streptococcal  infections.  Very low  levels  of 
ASDA activity were observed in the serum of young children between the ages 
of 6 months and 5 years. Indeed, the only human sera of the several hundred 
examined which failed to contain demonstrable ASDA activity were in this age 
group, perhaps because these individuals had fewer exposures to streptococcal 
infections.  Furthermore, sera capable in high dilution of neutralizing strepto- 
coccal DPNase  failed to inhibit a  similar  enzyme produced by Neurospora 
crassa. Taken together, the findings indicate that the ASDA activity of human 
serum is not a non-specific inhibition of DPNase, but rather, a specific antibody 
produced in response to exposure to appropriate strains of streptococci. 
The precise relationship  between the ASDA response following streptococcal 
infection and the ability of the offending organism to produce DPNase in vitro 
is  not clear  at the present  time. Lazarides and Bernheimer have shown  an 
association  between  DPNase  production  and  serological  type  of  Group  A 
streptococci  (7). Thus, they found that streptococci belonging to types 3, 4, 6, 
and 12 tend to produce DPNase with considerable regularity, and in keeping 
with this, most of the 15 patients from whom sera were obtained following in- 
fections with type 3 or type 12 streptococci showed a significant rise in ASDA 
titer (see Table III). On the other hand, Lazarides and Bernheimer found that 
not one of 13 strains of type 14 nor any of 38 strains of type 19 they studied 
produced  DPNase in vitro.  Despite this, a number of patients suffering from 
infections with these types of streptococci  showed substantial rises in ASDA 
titer (see Table III). Whether this is due to production of DPNase by some as 
yet untested strains of these types, or to a discrepancy between DPNase pro- 
duction in vivo and in vitro, or to other causes, remains undetermined. 
The observation  that antibodies  to streptococcal  DPNase are present in the 
serum of a very high percentage  of human beings and that the titer of these 
antibodies  rises subsequent  to streptococcal  infection makes it reasonable  to 
conclude that this enzyme is produced  in man during the course of such  in- 
fections. These studies, however, cast no further light on the question of what 
role, if any, DPNase may play in disease processes. The ability to measure 
antibodies to  streptococcal  DPNase  may have  some  application in  clinical 
medicine in the recognition of antecedent streptococcal  infections, especially in 
cases of glomerulonephritis  in which the strains most often associated with the 
disease (types 4, 12, and Red Lake) are, with only a few exceptions, known to 
be DPNase producers.  Also the finding that changes in ASDA levels did not 
always parallel  changes in ASO levels, and particularly the fact that in some 
cases ASDA titers were found to rise when ASO titers did not, may serve to 
broaden the usefulness of such antibody  studies in investigations concerned with 
the epidemiology of streptococcal  infections. A.  KELLNER~  E.  B.  FREEMAN',  AND  A.  S.  CARLSON  309 
SUMMARY 
Specific neutralizing antibodies directed against streptococcal DPNase were 
induced experimentally in rabbits and guinea pigs by the injection of partially 
purified preparations of the enzyme. Similar antibodies capable of inhibiting 
the  biological activity of the  enzyme were  found to occur naturally in  the 
serum of a very high percentage of human beings, and the titer of these anti- 
bodies  often  rose  sharply following  streptococcal  infections.  The  antibody 
response to streptococcal DPNase in general paralleled that to streptolysin O, 
though in some instances antibodies to one increased when those to the other 
did not. 
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